Notre Dame Team Targets CMV Drug Toxicity
Researchers are developing nanoparticles to deliver Ganciclovir to CMV-infected cells while limiting its buildup in the body.
Updated on Nov. 18, 2026 in Biotech

University of Notre Dame researchers Pilar Perez Romero and Prakash Nallathamby are developing a nanoparticle technology to reduce the toxicity of Ganciclovir, an FDA-approved medication for dangerous cytomegalovirus infections. The project is supported by the National Institutes of Health and is currently at the laboratory proof-of-concept stage.
Why it matters
Ganciclovir can accumulate to poisonous levels and is not recommended for infants or pregnant women, leaving some patients without a safe option. CMV can reactivate during pregnancy or transplantation, and the researchers aim to make the drug safely accessible to these groups.
The figures come from CMV prevalence statistics cited by the research team, showing one in three U.S. children infected by age five and more than half of adults infected by age 40. The source does not report clinical efficacy data, and the technology has not yet been tested in patients.
The players
University of Notre Dame
A private research university in South Bend, Indiana, known for its biomedical and nanotechnology research programs.
National Institutes of Health
The primary federal agency for biomedical and public health research in the United States, which is supporting this project.
The details
The team is adapting nanoparticles made of resorbable polymer and FDA-approved materials to encapsulate Ganciclovir and carry it to CMV-infected cells. An infected cell draws in an attached antibody and engulfs the nanoparticle, which releases the drug as it breaks down. The work uses blood samples from transplant patients obtained through the Indiana BioBank.
Timeline
Researchers are currently developing a laboratory proof of concept for the CMV treatment.
Tech Race
The effort builds on Ganciclovir, a long-approved antiviral whose toxicity has limited its use in pregnant women and infants. Encapsulating the drug in FDA-approved nanoparticle materials represents an attempt to extend the reach of an existing medication rather than develop a new compound.
If successful, the approach could eventually give pregnant women, infants, and transplant patients a safer way to receive treatment for CMV, a virus that about one in three U.S. children has contracted by age five. For now the technology remains in the laboratory and is not available to patients.
The takeaway
CMV is far more common than most people realize, and reducing drug toxicity could open safer treatment options for vulnerable groups. Readers interested in pregnancy and transplant health can discuss CMV screening with their healthcare providers.
Further reading
For more on related research, see the Biotech section.
Source note: This article includes information reported by Notre Dame News.






